Nov 30, 2021 8:30 am EST European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Nov 05, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 04, 2021 9:30 am EDT Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
Nov 04, 2021 7:30 am EDT Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
Oct 28, 2021 4:01 pm EDT Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
Oct 13, 2021 7:30 am EDT Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
Oct 04, 2021 7:30 am EDT Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
Oct 01, 2021 6:14 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sep 29, 2021 3:30 am EDT Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021